Company Overview and News

 
QUIK / QuickLogic Corporation DEF 14A 2017 PROXY

2018-03-16 sec.gov
Document UNITED STATES
Upvote Downvote

 
BRIEF-Quicklogic Corp Partners With Aldec For Its Embedded FPGA Technology

2018-02-20 reuters
* QUICKLOGIC CORP - PARTNERED WITH ALDEC TO PROVIDE SEAMLESS SIMULATION SUPPORT FOR ITS EMBEDDED FPGA TECHNOLOGY Source text for Eikon: Further company coverage:
Upvote Downvote

 
QUIK / QuickLogic Corporation 8-K EARNINGS RELEASE (Current Report)

2018-02-16 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549  FORM 8-K  CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 14, 2018 QuickLogic Corporation (Exact name of registrant as specified in its charter)             Delaware   000-22671   77-0188504 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.
Upvote Downvote

1
QuickLogic Corporation 2017 Q4 - Results - Earnings Call Slides

2018-02-15 seekingalpha
The following slide deck was published by QuickLogic Corporation in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

1
QuickLogic's (QUIK) CEO Brian Faith on Q4 2017 Results - Earnings Call Transcript

2018-02-15 seekingalpha
Ladies and gentlemen, good afternoon. At this time, I would like to welcome everyone to QuickLogic Fourth Quarter and Fiscal Year 2017 Conference Call. During the presentation, all participants will be in a listen-only mode. A question-and-answer session will follow the Company’s formal remarks [Operator Instructions]. I’ll repeat these instructions after management completes their prepared remarks.
Upvote Downvote

1
What's in the Offing for QuickLogic (QUIK) in Q4 Earnings?

2018-02-12 zacks
QuickLogic Corporation (QUIK - Free Report) is set to report fourth-quarter 2017 results on Feb 14. Notably, the company’s earnings have surpassed the Zacks Consensus Estimate in two of the four trailing quarters, with an average positive surprise of 9.2%.
Upvote Downvote

 
QUIK / QuickLogic Corporation / FRONTIER CAPITAL MANAGEMENT CO LLC - SC 13G/A (Passive Investment)

2018-02-07 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) QuickLogic Corporation. (Name of Issuer) COMMON STOCKS (Title of Class of Securities) 74837P108 (CUSIP Number) DECEMBER 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The r
Upvote Downvote

 
QUIK / QuickLogic Corporation / FRONTIER CAPITAL MANAGEMENT CO LLC - SC 13G/A (Passive Investment)

2018-02-07 sec.gov
SC 13G/A     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3) QuickLogic Corporation. (Name of Issuer) COMMON STOCKS (Title of Class of Securities) 74837P108 (CUSIP Number) DECEMBER 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * The r
Upvote Downvote

1
Time To Take A Full Position In QuickLogic Stock, As Production Wins Grow To 9 Consumer Products

2018-01-17 seekingalpha
I have returned to taking a full position in QuickLogic's (NASDAQ:QUIK) stock. A substantial development confirming the strategic update, given by management in the Q3 2017 conference call, has been revealed at the 2018 Consumer Electronic Show (CES). Consumer electronics manufacturers are shifting their focus to designing products from push to talk to low power consumption always-on and always-listening, which QuickLogic has designed the EOS S3 sensor processor chip around.
Upvote Downvote

2
Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling

2018-01-04 zacks
Chicago, IL – Jan 04, 2018 - Stocks in this week’s article include: Hecla Mining Company (HL - Free Report) , Cloud Peak Energy Inc. (CLD - Free Report) , Celsion Corporation (CLSN - Free Report) , QuickLogic Corporation (QUIK - Free Report) and Precision Drilling Corporation (PDS - Free Report) .
Upvote Downvote

 
5 Breakout Stocks Offering Terrific Returns

2018-01-03 zacks
Utilizing a breakout investment strategy is a natural choice for active investors who settle for nothing less than superlative returns. This involves zeroing in on stocks trading within a tight range and buying them when they step out of this band. In keeping with this approach, they are offloaded whenever they move below this narrow band. If properly implemented, such a strategy could deliver impressive returns.
Upvote Downvote

 
QuickLogic (QUIK) Up More Than 7%: Can the Rally Continue?

2017-12-27 zacks
QuickLogic Corporation (QUIK - Free Report) shares surged about 7.5% in yesterday’s trading session, outperforming the market.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 74837P108